US Pharma Tariff Alert

Executive summary Effective October 1, 2025, the U.S. will impose a 100% tariff on imported branded/patented pharmaceuticals unless companies have begun building U.S.-based manufacturing plants. Caveat. The Executive Order in this case is not yet out but for a statement by the Honble US President. The move is justified under national security and economic independence but raises serious concerns on drug pricing, healthcare costs, and trade relations. Indian Pharma companies face a choice: absorb costs, raise prices, or accelerate U.S. investment or identify other non US markets J the App by JustIDT examines the potential fall out of such a measure in the India Pharama Space